Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

Bibliographic Details
Main Authors:	L.C.V. Thomsen, A. Honoré, B. Almås, L.A.R. Reisæter, K. Førde, E.K. Kristoffersen, S.H. Kaada, G.K. Melve, S.I. Helle, G. Kvalheim, W. Azeem, J.R. Olsen, O.J. Halvorsen, L.A. Akslen, D. Bahn, K. Pantel, S. Riethdorf, H. Ragde, B.T. Gjertsen, A.M. Øyan, K.H. Kalland, C. Beisland
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320338428

Similar Items

Management of elderly mCRPC patients
by: Seiichiro Ozono
Published: (2015-12-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01)

Clinical case long-term care of the patient with mCRPC
by: I N Zaborskiy, et al.
Published: (2014-12-01)

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points
by: Fred Saad, et al.
Published: (2015-05-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Progress in the cryoablation and cryoimmunotherapy for tumor
by: Zenan Chen, et al.
Published: (2023-01-01)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Melissa Gamat-Huber, et al.
Published: (2020-09-01)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
by: Abhay Singh Gaur
Published: (2022-01-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
by: Nourridine Siewe, et al.
Published: (2022-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
by: Nourridine Siewe, et al.
Published: (2022-01-01)

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape
by: Manfred Wirth, et al.
Published: (2014-05-01)

Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
by: Ritesh P. Bhole, et al.
Published: (2023-12-01)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
by: Elisabet Cantó, et al.
Published: (2023-06-01)

Potential prognostic value of miR-132 and miR-212 expression in mCRPC patients
by: Mariano Pontico, et al.
Published: (2021-10-01)

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
by: Alexandre Mendonça Macedo, et al.
Published: (2023-02-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
by: Holden T Maecker, et al.
Published: (2021-08-01)

Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE
by: D. Mott, et al.
Published: (2020-07-01)

Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01)

Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients
by: Paulina Jonéus, et al.
Published: (2024-01-01)

Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort
by: Mariaconsiglia Ferriero, et al.
Published: (2023-09-01)

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling
by: Xiong Zhang, et al.
Published: (2021-04-01)

Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival
by: Gaetano eFacchini, et al.
Published: (2016-05-01)

350 Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
by: Jens Eickhoff, et al.
Published: (2021-11-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: S. Feyerabend, et al.
Published: (2020-07-01)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
by: Nicolas Delanoy, et al.
Published: (2021-03-01)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
by: Douglas G McNeel, et al.
Published: (2022-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis
by: Tobias Engel Ayer Botrel, et al.
Published: (2012-12-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
by: Jiang-Yi Wang, et al.
Published: (2022-01-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype
by: Vincent O’Neill, et al.
Published: (2023-11-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
by: Rosa Sciuto, et al.
Published: (2021-09-01)

Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
by: Senji Hoshi, et al.
Published: (2022-02-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)